Unmarried dads’ involvement with child secured during pregnancy

Men’s Health News
The best chance of "reeling-in" an unmarried father and building the foundations for a stable family life are the critical months of pregnancy, says new research from the University of Maryland.
"Unmarried dads are less likely to drift away if they are involved with their partner during this vital period when a family can begin to bond," says University Read more…

Australian men need the ‘right doctors’

Men’s Health News
Researchers from the University of Adelaide say regardless of the preconceived stereotype surrounding men and their health, Australian men are interested in talking about their health with the ‘right people’ and most men do not like the way that many doctors work.
The researchers from the University’s Freemasons Foundation Centre for Men’s Health say Australian men have been inaccurately portrayed as disinterested Read more…

Vitamin K appears to slow development of insulin resistance in elderly men

Men’s Health News
Vitamin K slowed the development of insulin resistance in elderly men in a study of 355 non-diabetic men and women ages 60 to 80 who completed a three-year clinical trial at the Jean Mayer Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA).
"Men who received vitamin K supplementation Read more…

Discovery of novel approach to suppress prostate cancer progression

Men’s Health News
Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.
Researchers say the upcoming study in the Proceedings of the National Academy of Sciences - now available online - may lead to a novel cancer therapy for humans.
"This research has far-reaching implications Read more…

Sciele Pharma And Plethora Solutions Announce Final Analysis Of PSD502 For Premature Ejaculation; All Primary And Secondary Endpoints Met In Phase III

Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced the final analysis of its European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation (’PE’). Read more…